$2.8M
1 filing since 2025 · latest Debt filed
Iantrek, Inc. is a pioneering medical technology company dedicated to enhancing glaucoma treatment through innovative solutions tailored for micro-interventional glaucoma surgery (MIGS). With a focus on addressing the pressing global challenge of glaucoma, a leading cause of irreversible blindness affecting over 75 million people worldwide, Iantrek is committed to improving patient outcomes and surgical precision in eye care.
What sets it apart
Iantrek stands out through its unique approach of combining micro-interventional tools and bio-tissue solutions that enhance both trabecular and suprachoroidal aqueous outflow pathways.
The CycloPen System is a micro-interventional device designed specifically for ophthalmologists. It facilitates the controlled creation or modification of cyclodialysis, effectively targeting the suprachoroidal outflow pathway, thereby enhancing surgical outcomes for glaucoma patients.
